Learn more about the innovations from our scientists
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
in-PharmaTechnologist, September 3, 2019
Pharmaceutical Technology, September 2, 2019
The mark of a great company